Skip to main content

The Problem
The Solution
About Us
Board of Directors
Contact Us
Press Releases
Site Map


  _________________________________________________________________________  ______________________

Developing a novel, blood-based test 

for enhancing cardiac catheterization rule in/rule out 

In the U.S. alone, more than 7 million patients enter the Emergency Room (ER) with complaints about chest pain every year. Chest pain is the second most common reason for ER visits in the US. 

ER physicians and cardiologists have tests (ECGs and troponins) to diagnose patients who have already had a heart attack. However, frequently these tests are inconclusive. Additionally, many patients experience chest pain due to non-cardiac reasons, including heartburn, esophageal reflux, and other non-life threatening conditions. Unfortunately, these patients may end up in a diagnostic "gray zone" and a significant number receive expensive and dangerous procedures they do not actually need, including cardiac catheterization ("caths") and coronary CT scans.

These are the patients who benefit the most from Prevencio's multiplexed proteomics HART™ test.

A​voiding unnecessary cardiac procedures and testing may save as much as $39,000 per patient.​ Additionally, ​unneeded cardiac procedures ​have patient risks, including contrasting dye toxicity and radiation exposure. These types of procedures account for 1.5% of all cancer in the U.S.

The HART™ test will be able to reduce patient risks and reduce costs for chest pain patients and healthcare systems around the world. 


Prevencio® is the registered trademark of Prevencio, Inc., a Delaware Corporation. Copyright (2014). All rights reserved. Diagnostic products described here are not for sale and have not been cleared by the FDA for commercial sale.





​​​​​​The HART™ blood-based test helps differentiate chest pain patients who have obstructive heart disease and need more extensive testing from those patients who can be safely sent home.